Total Funding
49
43
Total FundingVenture - Series Unknown raised
Growth Score
-2 pts
Heat Score
-7 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
45810
Curemark is a socially-driven biotechnology company focusing on the treatment of autism and other neurological diseases.
Joan Fallon: Founder & Chief Executive Officer
Matthew F. Heil, PhD: Chief Scientific Officer
About the Company
Curemark is a biopharmaceutical company that focuses on the development of novel therapies to treat serious diseases for which there are limited treatment options for patients in need. Their pipeline includes two Phase III clinical-stage programs for Autism and ADHD as well as three preclinical programs directed at Parkinson’s Disease,
Schizophrenia, and Addiction. All of their product candidates address severe neurologic diseases that are currently believed to be underserved by available approved therapies and represent large potential commercial market opportunities. They believe that their product candidates offer innovative therapeutic approaches and may have the potential to provide significant advantages relative to current therapies.
Women Founded
Women Led
